Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain—Reply

Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain—Reply Letters opioid use disorders. The emphasis on engagement in treat- Liraglutide for the Treatment ment after overdose reversal should be established nation- of Antipsychotic Drug-Induced Weight Gain wide. National efforts should expand the focus on educa- To the Editor Treatment with certain antipsychotic drugs tional campaigns to increase awareness of treatment (APDs) causes weight gain, leading to metabolic syndrome availability and reduce stigma among the general public, which and increasing cardiovascular-associated mortality. includes those with an opioid use disorder and their friends Although several pharmacologic agents and some behavioral and relatives. Of course, the success of such efforts is predi- interventions attenuate APD-elicited weight gain, the effects cated on treatment availability and having the health insur- are modest and rarely reduce body weight to baseline levels. ance needed to pay for it. In addition, as Saxon and In JAMA Psychiatry, Larsen et al report that the antidiabetic McCance-Katz note, research is urgently needed to better un- agent liraglutide, a glucagon-like peptide-1 (GLP-1) receptor derstand reasons for treatment dropout and how to improve agonist, reduces body weight, improves glucose tolerance, retention. A 2017 report from the National Academies of Sci- and decreases systolic blood pressure in patients with ences, Engineering, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain—Reply

Loading next page...
 
/lp/american-medical-association/liraglutide-for-the-treatment-of-antipsychotic-drug-induced-weight-BhPHWAuco0
Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2017.2702
Publisher site
See Article on Publisher Site

Abstract

Letters opioid use disorders. The emphasis on engagement in treat- Liraglutide for the Treatment ment after overdose reversal should be established nation- of Antipsychotic Drug-Induced Weight Gain wide. National efforts should expand the focus on educa- To the Editor Treatment with certain antipsychotic drugs tional campaigns to increase awareness of treatment (APDs) causes weight gain, leading to metabolic syndrome availability and reduce stigma among the general public, which and increasing cardiovascular-associated mortality. includes those with an opioid use disorder and their friends Although several pharmacologic agents and some behavioral and relatives. Of course, the success of such efforts is predi- interventions attenuate APD-elicited weight gain, the effects cated on treatment availability and having the health insur- are modest and rarely reduce body weight to baseline levels. ance needed to pay for it. In addition, as Saxon and In JAMA Psychiatry, Larsen et al report that the antidiabetic McCance-Katz note, research is urgently needed to better un- agent liraglutide, a glucagon-like peptide-1 (GLP-1) receptor derstand reasons for treatment dropout and how to improve agonist, reduces body weight, improves glucose tolerance, retention. A 2017 report from the National Academies of Sci- and decreases systolic blood pressure in patients with ences, Engineering,

Journal

JAMA PsychiatryAmerican Medical Association

Published: Nov 27, 2017

References